Skip to main content Accessibility help
×
Home
Hostname: page-component-dc8c957cd-qr7d4 Total loading time: 0.358 Render date: 2022-01-27T12:19:01.218Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "metricsAbstractViews": false, "figures": true, "newCiteModal": false, "newCitedByModal": true, "newEcommerce": true, "newUsageEvents": true }

Risks of neurobehavioral teratogenicity associated with prenatal exposure to valproate monotherapy: a systematic review with regulatory repercussions

Published online by Cambridge University Press:  26 February 2014

Salvatore Gentile*
Affiliation:
Department of Mental Health, ASL Salerno, Mental Health Centre n. 63, Cava de' Tirreni – Vietri Sul Mare, Salerno, Italy; Medical School “Federico II, ” Department of Neurosciences, University of Naples, Naples, Italy
*
*Address for correspondence: Salvatore Gentile, Department of Mental Health, ASL Salerno, Mental Health Centre n. 63 Cava de' Tirreni - Vietri Sul Mare, Piazza Galdi, 841013 Cava de’ Tirreni, Salerno, Italy. (Email: salvatore_gentile@alice.it)

Abstract

Beyond its formal indications (epilepsy, bipolar disorder, and migraine), valproate sodium (VPA) is widely used in a number of other clinical conditions. Recently, however, the U.S. Food and Drug Administration (FDA) issued a warning regarding a decrease in IQ scores in children prenatally exposed to the drug. For patients with migraine, the pregnancy labeling of VPA will be changed from Category “D” to “X.” VPA products will remain in pregnancy category “D” for treating epilepsy and manic episodes associated with bipolar disorder. Thus, this article aims to assess (through a computerized Medline/PubMed search) the neurobehavioral teratogenicity of valproate monotherapy, in order to evaluate alternative regulatory decisions. Reviewed information suggests a detrimental impact of antenatal valproate exposure on the global child neurodevelopment. Affected areas include not just reduced IQ scores, but also behavioral problems and a potential increase in the risk for a future diagnosis of attention-deficit/hyperactivity disorder. An increased risk of developing autism-spectrum disorders has also been reported. Thus, in my opinion, VPA should be assigned definitively to the Category “X,” independent of any considerations about its clinical indications, and should be strictly avoided during pregnancy, due to the demonstrated risk of both neurobehavioral and neurocognitive teratogenicity.

Type
Review Articles
Copyright
Copyright © Cambridge University Press 2014 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Johannessen Landmark, C, Larsson, PG, Rytter, E, Johannessen, SI. Antiepileptic drugs in epilepsy and other disorders--a population-based study of prescriptions. Epilepsy Res. 2009; 87(1): 3139.CrossRefGoogle Scholar
2.Hayes, J, Prah, P, Nazareth, I, etal. Prescribing trends in bipolar disorder: cohort study in the United Kingdom THIN primary care database 1995–2009. PLoS One. 2011; 6(12): e28725.CrossRefGoogle ScholarPubMed
3.Barbui, C, Conti, V, Purgato, M, etal. Use of antipsychotic drugs and mood stabilizers in women of childbearing age with schizophrenia and bipolar disorder: epidemiological survey. Epidemiol Psychiatr Sci. 2013; 22(4): 355361.CrossRefGoogle ScholarPubMed
4.Adedinsewo, DA, Thurman, DJ, Luo, YH, etal. Valproate prescriptions for nonepilepsy disorders in reproductive-age women. Birth Defects Res A Clin Mol Teratol. 2013; 97(6): 403408.CrossRefGoogle ScholarPubMed
5.Gentile, S. Prophylactic treatment of bipolar disorder in pregnancy and breastfeeding: focus on emerging mood stabilizers. Bipolar Disord. 2006; 8(3): 207220.CrossRefGoogle ScholarPubMed
6.Gentile, S. Bipolar disorder and pregnancy: to treat or not to treat? BMJ. 2012; 345: e7367.CrossRefGoogle ScholarPubMed
7.Vajda, FJ, O'Brien, TJ, Graham, JE, Lander, CM, Eadie, MJ. Dose dependence of fetal malformations associated with valproate. Neurology. 2013; 81(11): 9991003.CrossRefGoogle ScholarPubMed
8.Meador, KJ. Comment: valproate dose effects differ across congenital malformations. Neurology. 2013; 81(11): 1002.CrossRefGoogle ScholarPubMed
9.Pennell, PB, Klein, AM, Browning, N, etal. Differential effects of antiepileptic drugs on neonatal outcomes. Epilepsy Behav. 2012; 24(4): 449456.CrossRefGoogle ScholarPubMed
10.FDA Drug Safety Communication. Valproate anti-seizure products contraindicated for migraine prevention in pregnant women due to decreased IQ scores in exposed children. http://www.fda.gov/Drugs/DrugSafety/ucm350684.htm. Accessed: July 5, 2013.Google Scholar
11.Koch, S, Titze, K, Zimmermann, RB, etal. Long-term epilepsy and neuropsychological consequences of maternal anticonvulsant treatment during pregnancy for school-age children and adolescents. Epilepsia. 1999; 40(9): 12371243.CrossRefGoogle ScholarPubMed
12.Neurobehavioral Teratology Society. http://www.nbts.org/about-nbts/. Accessed February 15, 2014.Google Scholar
13.Steinhausen, HC, Losche, G, Koch, S, Helge, H. The psychological development of children of epileptic parents. I. Study design and comparative findings. Acta Paediatr. 1994; 83(9): 955960.CrossRefGoogle ScholarPubMed
14.Losche, G, Steinhausen, HC, Koch, S, Helge, H. The psychological development of children of epileptic parents. II. The differential impact of intrauterine exposure to anticonvulsant drugs and further influential factors. Acta Paediatr. 1994; 83(9): 961966.CrossRefGoogle ScholarPubMed
15.Koch, S, Jäger-Roman, E, Lösche, G, etal. Antiepileptic drug treatment in pregnancy: drug side effects in the neonate and neurological outcome. Acta Paediatr. 1996; 84(6): 739746.CrossRefGoogle Scholar
16.Adab, N, Jacoby, D, Smith, D, Chadwick, D. Additional educational needs in children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry. 2001; 70(1): 1521.CrossRefGoogle ScholarPubMed
17.Dean, CS, Hailey, H, Moore, SJ, etal. Long term health and neurodevelopment in children exposed to antiepileptic drugs before birth. J Med Genet. 2002; 39(4): 251259.CrossRefGoogle ScholarPubMed
18.Gaily, E, Kantola-Sorsa, E, Hiilesmaa, V, etal. Normal intelligence in children with prenatal exposure to carbamazepine. Neurology. 2004; 362(1): 2832.CrossRefGoogle Scholar
19.Eriksson, K, Viinikainen, K, Monkkonen, A, etal. Children exposed to valproate in utero—population based evaluation of risks and confounding factors for long-term neurocognitive development. Epilepsy Res. 2005; 65(3): 189200.CrossRefGoogle ScholarPubMed
20.Viinikainen, K, Eriksson, K, Monkkonen, A, etal. The effects of valproate exposure in utero on behavior and the need for educational support in school-aged children. Epilepsy Behav. 2006; 9(4): 636640.CrossRefGoogle ScholarPubMed
21.Thomas, SV, Ajaykumar, B, Sindhu, K, etal. Motor and mental development of infants exposed to antiepileptic drugs in utero. Epilepsy Behav. 2008; 13(1): 229236.CrossRefGoogle ScholarPubMed
22.Meador, KJ, Baker, GA, Browning, N, etal. for the NEAD Study Group. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N Engl J Med. 2009; 360(16): 15971605.CrossRefGoogle Scholar
23.McVearry, KM, Gaillard, WD, VanMeter, J, Meador, KJ. A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. Epilepsy Behav. 2009; 16(4): 609616.CrossRefGoogle ScholarPubMed
24.Cohen, MJ, Meador, KJ, Browning, N, etal. Fetal antiepileptic drug exposure: motor, adaptive, and emotional/behavioral/functioning at age 3 years. Epilepsy Behav. 2011; 22(2): 240246.CrossRefGoogle ScholarPubMed
25.Meador, KJ, Baker, GA, Browning, N, etal. for the NEAD Study Group. Effects of fetal antiepileptic drug exposure: outcomes at age 4.5 years. Neurology. 2012; 78(16): 12071214.CrossRefGoogle ScholarPubMed
26.Meador, KJ, Baker, GA, Browning, N, etal. for the NEAD Study Group. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurol. 2013; 12(3): 244252.CrossRefGoogle ScholarPubMed
27.Cohen, MJ, Meador, KJ, Browning, N, etal, for the NEAD study group. Fetal antiepileptic drug exposure: adaptive and emotional/behavioral functioning at age 6 years. Epilepsy Behav. 2013; 29(2): 308315.CrossRefGoogle Scholar
28.Meador, KJ, Baker, GA, Browning, N, etal, for the NEAD Study Group. Foetal antiepileptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain. 2011; 134(Pt 2): 396404.CrossRefGoogle ScholarPubMed
29.Adab, N, Kini, U, Vinten, J, etal. The longer term outcome of children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry. 2004; 75(11): 15751583.CrossRefGoogle ScholarPubMed
30.Vinten, J, Adab, N, Kini, U, etal, for the Liverpool and Manchester Neurodevelopment Study Group. Neuropsychological effects of exposure to anticonvulsant medication in utero. Neurology. 2005; 64(6): 949954.CrossRefGoogle ScholarPubMed
31.Vinten, J, Bromley, RL, Taylor, J, etal, on behalf of the Liverpool and Manchester Neurodevelopment Group. The behavioral consequences of exposure to antiepileptic drugs in utero. Epilepsy Behav. 2009; 14(1): 197201.CrossRefGoogle ScholarPubMed
32.Bromley, RL, Mawer, G, Love, J, etal, on behalf of the Liverpool and Manchester Neurodevelopment Group. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia. 2010; 51(10): 20582065.CrossRefGoogle ScholarPubMed
33.Shallcross, R, Bromley, RL, Irwin, B, etal, on behalf of the Liverpool/Manchester Neurodevelopment Group and the UK Epilepsy and Pregnancy Register. Child development following in utero exposure: levetiracetam vs sodium valproate. Neurology. 2011; 76(4): 383389.CrossRefGoogle ScholarPubMed
34.Bromley, RL, Mawer, G, Clayton-Smith, J, Baker, GA, on behalf of the Liverpool and Manchester Neurodevelopment Group. Autism spectrum disorders following in utero exposure to antiepileptic drugs. Neurology. 2008; 71(28): 19231924.CrossRefGoogle ScholarPubMed
35.Bromley, RL, Mawer, GE, Briggs, M, etal, on Behalf of the Liverpool and Manchester Neurodevelopment Group.. The prevalence of neurodevelopmental disorders in children prenatally exposed to antiepileptic drugs. J Neurol Neurosurg Psychiatry. 2013; 84(6): 637643.CrossRefGoogle ScholarPubMed
36.Johnson, CP, Myers, SM. American Academy of Pediatrics Council on Children with Disabilities. Identification and evaluation of children with autistic spectrum disorders. Pediatrics. 2007; 120(5): 11831215.CrossRefGoogle Scholar
37.Nadebaum, C, Anderson, V, Vajda, F, etal. The Australian brain and cognition and antiepileptic drugs study: IQ in school-aged children exposed to sodium valproate and polytherapy. J Int Neuropsychol Soc. 2011; 17(1): 133142.CrossRefGoogle ScholarPubMed
38.Nadebaum, C, Anderson, V, Vajda, F, etal. Language skills of school-aged children prenatally exposed to antiepileptic drugs. Neurology. 2011; 76(8): 719726.CrossRefGoogle ScholarPubMed
39.Cummings, C, Stewart, M, Stevenson, M, Morrow, J, Nelson, J. Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine. Arch Dis Child. 2011; 96(7): 643647.CrossRefGoogle ScholarPubMed
40.Kantola-Sorsa, E, Gaily, E, Isoaho, M, Korkman, M. Neuropsychological outcomes in children of mothers with epilepsy. J Int Neuropsychol Soc. 2007; 13(4): 642652.CrossRefGoogle ScholarPubMed
41.Christensen, J, Grønborg, TK, Sørensen, MJ, etal. Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA. 2013; 309(16): 16961703.CrossRefGoogle ScholarPubMed
42.Veiby, G, Daltvei, AK, Schjølberg, S, etal. Exposure to antiepileptic drugs in utero and child development: a prospective population-based study. Epilepsia. 2013; 54(8): 14621472.CrossRefGoogle ScholarPubMed
43.Rosner, B. Fundamentals of Biostatistics. Belmont, CA: Duxbury-Brooks/Cole; 2006.Google Scholar
44.Veiby, G, Engelsen, BA, Gilhus, NE. Early child development and exposure to antiepileptic drugs prenatally and through breastfeeding: a prospective cohort study on children of women with epilepsy. JAMA Neurol. 2013; 70(11): 13671374.CrossRefGoogle ScholarPubMed
45.Thomas, JM, Benham, AL, Gean, M, etal. Practice parameters for the psychiatric assessment of infant and toddlers (0-36 months). American Academy of Child and Adolescent Psychiatry. J Am Acad Child Adolesc Psychiatry. 1997; 36(10 Suppl): S21S36.CrossRefGoogle ScholarPubMed
46.Meisels, SJ, Provence, S. Screening and Assessment: Guidelines for Identifying Young Disabled and Developmentally Vulnerable Children and Their Families. Washington, DC: Zero to Three/National Center for Clinical Infants Program; 1989.Google Scholar
47.Gentile, S. SSRIs in pregnancy and lactation with emphasis on neurodevelopmental outcome. CNS Drugs. 2005; 19(7): 623633.CrossRefGoogle ScholarPubMed
48.Thapar, A, Fowler, T, Rice, F, etal. Maternal smoking during pregnancy and attention deficit hyperactivity disorder symptoms in offspring. Am J Psychiatry. 2003; 160(11): 19851989.CrossRefGoogle ScholarPubMed
49.Larsson, HJ, Eaton, WW, Madsen, KK. Risk factors for autism: perinatal factors, parental psychiatric history, and socioeconomic status. Am J Epidemiol. 2005; 161(10): 916925.CrossRefGoogle ScholarPubMed
50.Hultman, CM, Sparén, P, Cnattingius, S. Perinatal risk factors for infantile autism. Epidemiology. 2002; 13(4): 417423.CrossRefGoogle ScholarPubMed
51.Easterbrook, PJ, Berlin, JA, Gopalan, R, Matthews, DR. Publication bias in clinical research. Lancet. 1991; 337(8746): 867872.CrossRefGoogle ScholarPubMed
52.Wright, TL, Hoffman, LH, Davies, . Lithium teratogenicity. Lancet. 1970; 24; 2(7678): 876.CrossRefGoogle Scholar
53.Pennell, PB, Klein, AM, Browning, N, etal, for the NEAD Study Group. Differential effects of antiepileptic drugs on neonatal outcomes. Epilepsy Behav. 2012; 24(4): 449456.CrossRefGoogle ScholarPubMed
54.Fox, AW, Diamond, ML, Spiering, EL. Migraine during pregnancy: options for therapy. CNS Drugs. 2005; 19(6): 465481.CrossRefGoogle ScholarPubMed
55. Flunarizine. http://db.cbg-meb.nl/veegactie/csp/Flunarizine-December2010.doc. Accessed: July 14, 2013.Google Scholar
56.Holmes, LB, Hernandez-Diaz, S. Newer anticonvulsants: lamotrigine, topiramate and gabapentin. Birth Defects Res A Clin Mol Teratol. 2012; 94(8): 599606.CrossRefGoogle ScholarPubMed
57.National Institute for Health and Clinical Excellence. The epilepsies: The diagnosis and management of the epilepsies in adults and children in primary and secondary care. http://www.nice.org.uk/nicemedia/live/13635/57784/57784.pdf. Accessed: July 16, 2013.Google Scholar
58.Campbell, E, Kennedy, F, Irwin, B, etal. Malformation risks of antiepileptic drug monotherapies in pregnancy. J Neurol Neurosurg Psychiatry. 2013; Nov; 84(11): e2.CrossRefGoogle Scholar
59.Gentile, S. Lithium in pregnancy: the need to treat, the duty to ensure safety. Exp Opin Drug Saf. 2012; 11(3): 425437.CrossRefGoogle ScholarPubMed
60.Vajda, FJ, Graham, J, Roten, A, etal. Teratogenicity of the newer antiepileptic drugs—the Australian experience. J Clin Neurosci. 2012; 19(1): 5759.CrossRefGoogle ScholarPubMed
61.Gentile, S. Antipsychotic therapy during early and late pregnancy: a systematic review. Schizophr Bull. 2010; 36(3): 518544.CrossRefGoogle ScholarPubMed
62.Kjaer, D, Christensen, J, Becha, BH, etal. Preschool behavioral problems in children prenatally exposed to antiepileptic drugs—a follow-up study. Epilepsy Behav. 2013; 29(2): 407411.CrossRefGoogle ScholarPubMed
63.Boden, R, Lundgren, M, Brandt, L, etal. Risks of adverse pregnancy and birth outcomes in women treated or not treated with mood stabilisers for bipolar disorder: population based cohort study. BMJ. 2012; 345: e7085.CrossRefGoogle ScholarPubMed
64. Mayo Clinic.Epilepsy and pregnancy: what you need to know. http://www.mayoclinic.com/health/pregnancy/PR00123. Accessed: September 30, 2013.Google Scholar
65.Frederick, IO, Qiu, C, Enquobahrie, DA, etal. Lifetime prevalence and correlates of migraine among women in a Pacific Northwest pregnancy cohort study. Headache. In press. doi: 10.1111/head.12206.CrossRefGoogle Scholar
66.Wright, G, Patel, M. Focal migraine and pregnancy. BMJ. 1986; 293(6561): 15571558.CrossRefGoogle Scholar
67.MacGregor, EA. Headache in pregnancy. Neurol Clin. 2012; 30(3): 835866.CrossRefGoogle ScholarPubMed
21
Cited by

Send article to Kindle

To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Risks of neurobehavioral teratogenicity associated with prenatal exposure to valproate monotherapy: a systematic review with regulatory repercussions
Available formats
×

Send article to Dropbox

To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

Risks of neurobehavioral teratogenicity associated with prenatal exposure to valproate monotherapy: a systematic review with regulatory repercussions
Available formats
×

Send article to Google Drive

To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

Risks of neurobehavioral teratogenicity associated with prenatal exposure to valproate monotherapy: a systematic review with regulatory repercussions
Available formats
×
×

Reply to: Submit a response

Please enter your response.

Your details

Please enter a valid email address.

Conflicting interests

Do you have any conflicting interests? *